Dilated Cardiomyopathy Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Renovacor, Pfizer, Longeveron, MyoKardia, Vericel, Tenaya Therapeutics, Cardior Pharmaceuticals

September 20 05:46 2023
Dilated Cardiomyopathy Market Forecasts by DelveInsight Signal Groundbreaking Growth by 2032 | Renovacor, Pfizer, Longeveron, MyoKardia, Vericel, Tenaya Therapeutics, Cardior Pharmaceuticals
Delveinsight Business Research LLP
The Dilated Cardiomyopathy Market size in the 7MM was USD 303.7 million in 2022, and it is expected to grow by 2032. As per DelveInsight, the Dilated Cardiomyopathy Market is anticipated to evolve immensely in the coming years owing to the increasing patient population of Dilated Cardiomyopathy (DCM) along with the anticipated drug launches.

DelveInsight’s “Dilated Cardiomyopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Dilated Cardiomyopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).

The report covers emerging Dilated Cardiomyopathy drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current Dilated Cardiomyopathy treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market. 

Dilated Cardiomyopathy: An Overview

Dilated Cardiomyopathy (DCM) is the most common type of non-ischemic heart muscle disease, occurring mostly in adults. It affects the lower chamber of the ventricle and the upper chamber of the atria of the heart. Normally, the disease starts in the left ventricle and the heart muscle begins to dilate, which means that it stretches and becomes thinner. As a result, the inside of the chamber enlarges. The problem often spreads to the right ventricle and then to the atria. As the heart chambers dilate, the heart muscle does not contract normally and cannot pump blood very well. As the heart becomes weaker, which in some situations leads to heart failure.

The WHO defines DCM as a serious cardiac disorder in which structural or functional abnormalities of the heart muscle can lead to substantial morbidity and mortality owing to complications such as heart failure and arrhythmia. Common symptoms of heart failure include shortness of breath, fatigue, and swelling of the ankles, feet, legs, abdomen, and veins in the neck. It can also lead to heart valve problems, arrhythmias, and blood clots in the heart.

DCM can be diagnosed based on medical history (symptoms and family history), physical exam, blood tests, electrocardiogram (ECG or EKG), chest X-ray, echocardiogram, and others. Myocardial biopsy has also been used for the diagnosis of DCM.

Dilated Cardiomyopathy Market Key Facts

  • The highest number of prevalent cases of Dilated cardiomyopathy were recorded in the United States, with 1,052,000+ cases making up about 41% of the total 7MM patient pool of Dilated cardiomyopathy.

  • Among the major five European countries, Germany had the highest prevalent cases of Dilated cardiomyopathy with 269,000+ cases in 2022, followed by France, the United Kingdom, and Italy. On the other hand, Spain had the lowest prevalent cases of Dilated cardiomyopathy, i.e., 166,000+ cases in 2022.

  • As per DelveInsight’s analysis, in 2022 Japan accounted for 424,000+ DCM cases.

Dilated Cardiomyopathy Market

Dilated Cardiomyopathy Market

The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted market size by analyzing the impact of current and emerging Dilated Cardiomyopathy pipeline therapies. It also thoroughly assesses the Dilated Cardiomyopathy market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.

The report gives complete details of the market trend for each marketed Dilated Cardiomyopathy drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.

Dilated Cardiomyopathy Epidemiology Assessment 

The epidemiology section provides insights into the historical, current, and forecasted Dilated Cardiomyopathy epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted Dilated Cardiomyopathy epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pools, future trends, and views of key opinion leaders. 

The Report Covers the Dilated Cardiomyopathy Epidemiology, Segmented as –

  • Total Prevalent Population of Dilated Cardiomyopathy

  • Total Diagnosed Population of Dilated Cardiomyopathy

  • Familial and non-familial cases of Dilated Cardiomyopathy

  • Gender-Specific Cases of Dilated Cardiomyopathy

  • Total Treated Cases of Dilated Cardiomyopathy

Dilated Cardiomyopathy Drugs Uptake and Pipeline Development Activities

The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Dilated Cardiomyopathy market or expected to be launched during the study period. The analysis covers the Dilated Cardiomyopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the market dynamics by drug sales, the most rapid drug uptake, and the reasons behind the maximal use of particular drugs. Additionally, it compares the Dilated Cardiomyopathy drugs based on their sale and market share.

The report also covers the Dilated Cardiomyopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key Dilated Cardiomyopathy companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Learn How the Dilated Cardiomyopathy Market Will Evolve and Grow by 2032 @ 


Dilated Cardiomyopathy Therapeutics Analysis

Currently, there are therapies for the treatment of DCM, however, off-label therapies like beta-blockers, angiotensin receptor-neprilysin inhibitors, angiotensin-converting enzyme inhibitors (ACEi), aldosterone antagonists, and diuretics are available to help control symptoms and prevent complications.

To further improve the treatment outlook, several major pharma and biotech companies are developing therapies for Dilated Cardiomyopathy. Currently, Pfizer is leading the therapeutics market with its Dilated Cardiomyopathy drug candidates in the most advanced stage of clinical development. Current clinical HCM therapies focus on symptomatic management and prevention of sudden cardiac death. Symptomatic management includes the use of pharmacological agents to improve cardiac relaxation and energetics, as well as septal reduction strategies to relieve outflow tract obstruction. Additionally, automatic implantable cardiac defibrillators and antiarrhythmic drugs are used in the prevention of sudden cardiac death.

Dilated Cardiomyopathy Companies Actively Working in the Therapeutics Market Include

  • Renovacor

  • Pfizer

  • Longeveron

  • MyoKardia

  • Berlin Cures

  • Vericel

  • Tenaya Therapeutics

  • Cardior Pharmaceuticals

  • Help Therapeutics

And Many Others

Emerging and Marketed Dilated Cardiomyopathy Therapies Covered in the Report Include:

  • PF-07265803/ARRY-371797/ARRY-797: Pfizer

  • BC007: Berlin Cures GmbH

  • Ifetroban: Cumberland Pharmaceuticals

  • Danicamtiv/MYK-491: MyoKardia

  • CAP-1002: Capricor Therapeutics

  • Ixmyelocel-T: Vericel

And Many More

Download the Sample Report to Learn More About the Key Companies and Emerging Therapies @


Table of Content (TOC)

1. Key Insights

2. Executive Summary 

3. Dilated Cardiomyopathy Competitive Intelligence Analysis

4. Dilated Cardiomyopathy Market Overview at a Glance

5. Dilated Cardiomyopathy Disease Background and Overview

6. Dilated Cardiomyopathy Patient Journey

7. Dilated Cardiomyopathy Patient Population and Epidemiology Trends (In the US, EU5, and Japan)

8. Dilated Cardiomyopathy Treatment Algorithm, Current Treatment, and Medical Practices

9. Dilated Cardiomyopathy Unmet Needs

10. Key Endpoints of Dilated Cardiomyopathy Treatment

11. Dilated Cardiomyopathy Marketed Therapies

12. Dilated Cardiomyopathy Emerging Drugs and Latest Therapeutic Advances

13. Dilated Cardiomyopathy Seven Major Market Analysis

14. Attribute Analysis

15. Dilated Cardiomyopathy Market Outlook (In US, EU5, and Japan)

16. Dilated Cardiomyopathy Companies Active in the Market

17. Dilated Cardiomyopathy Access and Reimbursement Overview

18. KOL Views on the Dilated Cardiomyopathy Market

19. Dilated Cardiomyopathy Market Drivers

20. Dilated Cardiomyopathy Market Barriers

21. Appendix

22. DelveInsight Capabilities

23. Disclaimer

*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.

Request the Sample PDF to Learn More About the Key Offerings of the Report @




About DelveInsight

DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.

Upgrade your industry insights with our comprehensive medical devices market assessment reports. Visit to gain a strategic edge through expert analysis and in-depth coverage of the latest trends, innovations, and market dynamics, at @ Healthcare Market Research Services

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/oncology